+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cyclin D1 expression in ductal carcinoma in situ, atypical ductal hyperplasia and usual ductal hyperplasia: An immunohistochemical study



Cyclin D1 expression in ductal carcinoma in situ, atypical ductal hyperplasia and usual ductal hyperplasia: An immunohistochemical study



Pathology International 50(7): 527-530



The cell cycle regulatory gene, Cyclin D1, plays a critical role in the growth and progression of several types of human cancer, including breast cancer. Immunohistochemical study of Cyclin D1 expression has been extensively reported in invasive ductal carcinoma (IDC). In contrast, there have been few reports concerning Cyclin D1 expression in ductal carcinoma in situ (DCIS) and their positive rates are variable. The differences in the reported frequency may be largely due to the differences in antibodies used, immunohistochemical methods and the positive cut-off point. However, we speculated that the strictness of diagnosis of DCIS might be somewhat responsible for these differences in frequency. Therefore, we selected cases of DCIS by carefully eliminating cases of predominantly intraductal carcinoma (PIC). Moreover, to clarify whether Cyclin D1 expression is involved in multistep carcinogenesis or the progression of human breast cancer, we immunohistochemically investigated Cyclin D1 expression in 57 DCIS, 10 atypical ductal hyperplasia (ADH), 70 usual ductal hyperplasia (UDH), 44 PIC and 92 IDC. Cyclin D1 expression was detected in 41 DCIS cases (72%), 22 PIC cases (50%) and 40 IDC cases (43%). No expression of Cyclin D1 was observed in either ADH or UDH. There were no significant correlations between Cyclin D1 expression and histological grade or estrogen receptor expression in DCIS. These results suggest that Cyclin D1 expression may play an important role in the early stages of carcinogenesis, and that immunohistochemical detection of Cyclin D1 expression may be helpful in differentiating low-grade DCIS from ADH.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010405405

Download citation: RISBibTeXText

PMID: 10886733

DOI: 10.1046/j.1440-1827.2000.01076.x


Related references

Cyclin D1 expression in usual hyperplasia, atypical ductal hyperplasia and low nuclear grade ductal carcinoma in situ of the breast An immunohistochemical study. Journal of Pathology 187(SUPPL ): 25A, 1999

Thymidine kinase 1 expression in atypical ductal hyperplasia significantly differs from usual ductal hyperplasia and ductal carcinoma in situ: A useful tool in tumor therapy management. Molecular Medicine Reports 2(6): 923-929, 2009

Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ. Archives of Pathology and Laboratory Medicine 140(7): 686-689, 2017

Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. Journal of Pathology 198(4): 458-467, 2002

Expression of cyclins in ductal hyperplasia, atypical ductal hyperplasia and ductal carcinoma in situ of the breast. Yonsei Medical Journal 41(3): 345-353, 2000

Expression of cyclin-dependent kinase inhibitor, p27 in ductal carcinoma in situ and atypical ductal hyperplasia of breast. Laboratory Investigation 78(1): 22A, 1998

Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Modern Pathology 3(4): 449-454, 1990

Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. Journal of Pathology 184(4): 396-400, 1998

Differences and Relationships Between Normal and Atypical Ductal Hyperplasia, Ductal Carcinoma In Situ, and Invasive Ductal Carcinoma Tissues in the Breast Based on Raman Spectroscopy. Applied Spectroscopy 71(2): 300-307, 2018

Interphase cytogenetic study of chromosomes 7, 18 and X in mammogram detected atypical ductal hyperplasia and ductal carcinoma in situ. Modern Pathology 9(1): 18A, 1996

P63 and cytokeratin8/18 expression in breast, atypical ductal hyperplasia, ductal carcinoma in situ and invasive duct carcinoma. Journal of the Egyptian National Cancer Institute 19(3): 202-210, 2007

Ductal carcinoma in situ and atypical ductal hyperplasia of the breast diagnosed at stereotaxic core neddle biopsy A multiinstitutional study. Virchows Archiv 435(3): 193, Sept, 1999

Solid Papillary Ductal Carcinoma In Situ Versus Usual Ductal Hyperplasia in the Breast: A Potentially Difficult Distinction Resolved by Cytokeratin 5/6. Breast Diseases: A Year Book Quarterly 18(1): 64-65, 2007

Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6. Human Pathology 37(7): 787-793, 2006

Atypical ductal hyperplasia and ductal carcinoma in situ of the breast associated with perineural invasion. Human Pathology 32(8): 785-790, 2001